Results 141 to 150 of about 12,579 (242)

Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice. [PDF]

Vaccines (Basel), 2023
Wilken L, Stelz S, Agac A, Sutter G, Prajeeth CK, Rimmelzwaan GF.   +5 more
europepmc   +1 more source

Late‐breaking trials in IBD

United European Gastroenterology Journal, Volume 13, Issue 9, Page 1818-1839, November 2025.
wiley   +1 more source

ISEV2025 Abstract Book

Journal of Extracellular Vesicles, Volume 14, Issue S1, October 2025.
wiley   +1 more source

The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation

Frontiers in Immunology
IntroductionModified Vaccinia Virus Ankara (MVA) is a safe vaccine vector inducing long- lasting and potent immune responses. MVA-mediated CD8+T cell responses are optimally induced, if both, direct- and cross-presentation of viral or recombinant ...
Ylenia Longo, Sara Moreno Mascaraque, Giuseppe Andreacchio, Julia Werner, Ichiro Katahira, Elena De Marchi, Anna Pegoraro, Robert Jan Lebbink, Karl Köhrer, Patrick Petzsch, Ronny Tao, Francesco Di Virgilio, Elena Adinolfi, Ingo Drexler   +13 more
doaj   +1 more source

Modified Vaccinia Virus Ankara as a Potential Biosafety Level 2 Surrogate for African Swine Fever Virus in Disinfectant Efficacy Tests. [PDF]

Pathogens, 2022
Rhee CH, Her M, Jeong W.
europepmc   +1 more source

Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression [PDF]

, 2009
Michael H. Lehmann, Wolfgang Kastenmüller, Judith D. Kandemir, Florian Brandt, Yasemin Suezer, Gerd Sutter   +5 more
openalex   +1 more source

Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions

Vaccines
The 2022 global mpox outbreak, caused by clade IIb of the monkeypox virus (MPXV), prompted emergency use authorisation of the Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccine, previously approved for smallpox prevention.
Joanne Byrne, Patrick D. M. C. Katoto, Bruce Kirenga, Wilber Sabiiti, Andrew Obuku, Virginie Gautier, Patrick W. G. Mallon, Eoin R. Feeney   +7 more
doaj   +1 more source

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome. [PDF]

PLoS Pathog, 2022
PLOS Pathogens Editors.
europepmc   +1 more source

Immunomonitoring technologies for the evaluation of Modified Vaccinia Virus Ankara expressing HIV-1 nef as a vaccine against AIDS [PDF]

, 2010
Sarah Kutscher
openalex   +1 more source

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA prime - Modified Vaccinia Ankara (MVA) boost HIV-1 vaccine regimen [PDF]

, 2017
Prime-boost vaccination strategies against HIV-1 often include multiple variants for a given immunogen for better coverage of the extensive viral diversity.
Bakari, M, Bauer, A, Biberfeld, G, Geldmacher, C, Haule, A, Hoelscher, M, Joseph, S, Kaluwa, B, Kijak, G, Kroidl, A, Lueer, C, Lyamuya, E, Maboko, L, Mann, P, Marovich, M, McCormack, S, Missanga, M, Munseri, PJ, Mwakatima, M, Nilsson, C, Podola, L, Robb, ML, Sandström, E, Sudi, L, Tovanabutra, S, Wahren, B   +25 more
core